Sorrento, Yuhan create a JV for checkpoint drugs

San Diego-based Sorrento Therapeutics ($SRNE) is forming a joint venture with South Korea's Yuhan to develop immune checkpoint antibodies for cancer. Yuhan is seeing ImmuneOncia Therapeutics with a $10 million payment. Release